Discussion
The treatment of patients with comorbid BD and OCD appears rather problematic. It seems that mood stabilizers alone do not suffice to control obsessive-compulsive symptoms (5) , although there have been some positive experiences with lithium (6) , as well as with topiramate and lamotrigine (1) . The use of antidepressants risks inducing mania or rapid cycling (1) , and treatment of mania with classic neuroleptic drugs may lead to worsened obsessive-compulsive symptoms (3) . However, there seems to be some hope in the use of the newer, atypical antipsychotic agents. The role of these drugs in treating BD is now well established (7) , and there is some evidence that such agents are efficacious in treating OCD. Most reports concern cases of refractory OCD (8-10), but it has been suggested that such cases could imply bipolarity (5) .
Owing to the prognostic and therapeutic implications mentioned, it is most important to carefully assess BD patients for the existence of obsessive-compulsive symptoms. It should be borne in mind that specifically oriented questioning is necessary to disclose such symptoms, given that patients often conceal them out of ignorance or embarrassment (4) , as in the case we report. Atypical antipsychotics such as olanzapine act favourably on obsessive-compulsive symptoms, as well as on BD, and could thus be of use in patients with comorbid BD and OCD. Petros Petrikis, MD; Christina Andreou, MD Vasilis P Bozikas, MD PhD; Athanasios Karavatos, MD, PhD Thessaloniki, Greece
Monoamine Oxidase Inhibitors and Subarachnoid Hemorrhage
Dear Editor: Hypertensive crisis with monoamine oxidase inhibitor (MAOI) use has been reported in the literature and carries an overall risk of less than 1% (1). The reported reactions were triggered by diet noncompliance or by the use of concomitant medications. Specific agents responsible for these crises include tricyclic antidepressants (TCAs), meperidine, levodopa, and hay fever and cold remedies (2) (3) (4) . However, spontaneous hypertensive reactions have also been described (1) . Here, we present the first case of a subarachnoid hemorrhage (SAH) observed over the last 35 years that was likely caused by a hypertensive crisis secondary to MAOI use (5).
Case Report
A man, aged 52 years, with a long-standing history of treatment-refractory atypical depression presented to hospital complaining of a severe headache. The patient's medical history did not suggest any risk factors for SAH. Five weeks prior to admission, he had begun taking oral tranylcypromine with a dosage escalating to 20 mg daily. One week after starting this medication, he complained of the "worst headache of [his] life" after consuming a meal of chicken teriyaki that included a half-tablespoon of soy sauce. When he presented at a local emergency room, his blood pressure was elevated to a systolic pressure of 210 mmHg. A noncontrast CT scan was performed. The scan revealed 2 small, hyperdense foci in the left frontal lobe and left lateral occipital lobe, with surrounding edema, consistent with an SAH. There was no evidence of hydrocephalus. His GCS score was found to be 13 to 14, and we were consulted in regard to delirium. The patient was unable to follow commands and, interestingly, had evidence of perseveration. Routine investigations were normal. A cerebral angiogram showed no evidence of aneurysm or vascular malformation and only showed vasospastic changes along branches of the left middle cerebral artery. An investigation for vasculitis was also negative.
His delirium was left untreated so that his level of consciousness could be accurately followed. The tranylcypromine and a neuroleptic for the treatment of delirium were withheld owing to concerns on the part of the neurosurgery service. The delirium resolved, and he was discharged after 17 days.
On follow-up, the patient opted for no further treatment with medication and was offered a trial of interpersonal therapy. He relied upon Tylenol 3 to manage his headache symptoms, which dissipated over time.
Discussion
Multiple factors led to the conclusion that this SAH was triggered by MAOI use. The patient's consumption of soy sauce, a recent increase in tranylcypromine dosage, ingestion of tranylcypromine close to mealtime, and a medical history devoid of SAH risk factors all suggest that MAOI use was a precipitating factor. Further, negative angiography and a laboratory workup helped rule out other possible causes. It is interesting to note that the patient's outpatient psychiatrist considered treating his depression with a TCA, which has been cited to precipitate SAH in some patients (4) . MAOI agents can be effective antidepressants, but as this case highlights, physicians and patients should be aware of their propensity to cause SAH. 
Beyond Haloperidol: Teaching Emergency Medicine Residents to Manage Acute Agitation and Aggression in the Emergency Department
Dear Editor:In emergency departments, haloperidol is the antipsychotic most frequently used to manage violent patients (1) . Although psychiatrists use various typical and atypical antipsychotics for this indication (2), emergency physicians continue to favour haloperidol. It is a safe and reliable medication for acute aggression (1), but there are additional factors to consider. For example, most patients requiring an antipsychotic for ongoing treatment will be prescribed a novel or atypical antipsychotic such as risperidone, olanzapine, or quetiapine. Using the same medication for both acute and ongoing treatment improves continuity, reduces risk of relapse while switching medications, and reduces the risk of medication interactions. Moreover, alternate strategies are useful if a patient states a strong medication preference or has experienced an allergic or side effect reaction to a particular medication. Further, patients will sometimes require intramuscular (IM) antipsychotics. However, in Canada, only typical antipsychotics are available in IM formulation. In the US, ziprasidone IM has recently been approved for treatment of acute agitation in patients with schizophrenia (3), while olanzapine IM is moving toward approval in Canada and in the US (3). Many typical antipsychotics are as safe and effective as haloperidol and can be given IM. These include trifluoperazine, fluphenazine, thiothixene, and loxapine (1, 2) . With regard to the latter, loxapine has a 5-HT 2 -dopamine D 2 receptor occupancy ratio more characteristic of atypical than typical antipsychotics and, thus, a lower risk of extrapyramidal symptoms (2) .
Many hospitals have psychiatrists readily available to the emergency department, yet emergency physicians still regularly manage patients showing acute aggression. Emergency physicians are intermittently exposed to continuing medical education, to pharmaceutical company presentations, and to informal discussions with psychiatry staff regarding medication management of aggression. Nevertheless, haloperidol remains the antipsychotic of choice.
At our centre, postgraduate year 1 emergency medicine (EM) residents are required to complete a 1-month psychiatry rotation. During residency year 2002-2003, EM residents for the first time completed an emergency psychiatry rotation. Each resident was specifically educated in the management of agitation and aggression. This included a didactic session, teaching focused on cases, and supervised case management. At the beginning of their rotations, all 4 EM residents were aware of the haloperidol 5 mg plus lorazepam 2 mg approach to managing aggression. By the end of the rotation, residents were comfortable with some other approaches, including use of loxapine, risperidone, and olanzapine. One resident had the opportunity in the emergency department to use loading dosages of olanzapine 20 mg for 3 different patients showing agitation, with excellent benefit (4). Moreover, in ensuing months, EM residents continued to use these strategies and to discuss them with colleagues.
EM residents benefit from a specific rotation in emergency psychiatry because it is so relevant to their future practice. Further, psychiatry patients benefit from a more patient-centred, individualized approach to medication management, even in the acute setting. 
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